Eli Lilly to cease supplying etesevimab + bamlanivimab combination in the EU and withdraw its application for full authorization.
Eli Lilly has withdrawn its application for European Medicines Agency approval of its COVID-19 antibody therapy combination, citing a lack of demand from member states.
The antibody combination first gained emergency authorization from the EMA in March (shortly after Ronapreve). It had been undergoing a rolling review process for full marketing authorization, but on 29 October, Lilly wrote to the regulator to withdraw from the process, stating: “Given current demand from EU member states, Lilly forecasts that no additional/new drug substance manufacturing campaigns will be needed for the foreseeable future”. Eli Lilly remains a major supplier to the US COVID-19 antibody market.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.